COGENT BIOSCIENCES: MASSIVE UPSIDE POTENTIAL! h
Post# of 3
https://www.aviseanalytics.com/cogent-bioscie...potential/
Cogent Biosciences (COGT) is a clinical-stage biotechnology company targeting underlying causes of genetic dysfunction that cause diseases such as cancers, autoimmune disorders and rare diseases.
In October 2021, H.C Wainwright initiated coverage for the stock with a “Buy” rating and a price target of $25, which was later revised to $31, showing a massive upside potential.
We take a look at the Company in our coverage today.
Learn More